

## **Clonidine action in spontaneously hypertensive rats (SHR) depends on the GABAergic system function**

**B. Goźlińska and H. Czyżewska-Szafran**

Department of Pharmacology, Drug Institute, Warsaw, Poland

Accepted June 12, 1998

**Summary.** The effect of  $\gamma$ -aminobutyric acid (GABA)<sub>A</sub> antagonists (bicuculline, picrotoxin) on clonidine hypotension in spontaneously hypertensive (SHR) and Wistar Kyoto (WKY) rats were examined. The GABA turnover changes after clonidine injection in both strains were also studied. Administration of clonidine alone induced the stronger decrease of systolic blood pressure (SBP) in SHR. Co-dosage of clonidine with these agents reduced its hypotensive effect in dose dependent manner and the effectiveness of both antagonists was higher in SHR. We find that clonidine stimulates GABA synthesis in the hypothalamus and the pons-medulla in both strains but the GABA turnover rate is significantly slower in SHR. Therefore, the differences in inhibitory action of GABA<sub>A</sub> receptor antagonists between WKY and SHR rats may be explained by central GABAergic system dysfunction in the hypertension. Our results indicate that the down regulation of the GABAergic system observed in hypertension may be compensated by the action of clonidine.

**Keywords:** Amino acids – Clonidine – GABA<sub>A</sub> receptor antagonists – GABA turnover – SHR – WKY rats

### **Introduction**

Clonidine (CLON) is a well known centrally acting antihypertensive drug, which produces hypotensive effect inducing by various mechanisms at the CNS level (Karege and Gaillard 1990, Weekly et al., 1985). Some authors (Pittaluga and Raiteri, 1988) suggest that GABAergic transmission plays an important role in the mechanism of clonidine action. The results obtained by Marmo et al. (1987) indicate that GABA<sub>A</sub> receptor antagonist bicuculline decreases antihypertensive effect of clonidine in the same manner in normotensive (WKY) and hypertensive rats (SHR). It is worth noting, that our previous results (Czyżewska-Szafran and Wutkiewicz, 1986) and those of others (Wible et al., 1988; Sasaki et al., 1992; Singewald et al., 1992), have

shown that GABAergic inhibition is impaired in hypertension. This implies that GABA<sub>A</sub> receptors antagonists action should be more pronounced in hypertensive rats. Lately, our studies (Czyżewska-Szafran et al., 1991) performed only on SHR rats demonstrate that clonidine is able to evoke evident changes in GABAergic indices. Therefore, the goal of the current studies is to explore the contribution of  $\gamma$ -aminobutyric acid (GABA) to the clonidine hypotension in SHR in comparison with WKY rats.

## Material and methods

### *Animals*

Age-matched female 15 week-old rats weighing  $230 \pm 10$  g (WKY),  $180 \pm 8$  g (SHR) were used. Rats were maintained on a 12/12 h light/dark cycle, at a constant temperature, five to cage with free access to food and water.

### *Blood pressure recording*

SBP was measured in conscious rats by the indirect tail-cuff method using a pulse detector connected to a computer (IITC. Inc. Mod. 179, Woodland Hills, CA 91367.1253, USA). Animals were maintained at a temperature of  $26 \pm 1^\circ\text{C}$  during blood pressure recording sessions. All rats were acclimated to the measuring device for 3 days prior to measurements. Mean value from at least 8 consecutive readings for computation was used. Only rats with stable basal SBP were taken for the experiment. SHR or WKY rats received intraperitoneally single clonidine doses of 5, 10 or  $20\mu\text{g/kg}$ . SBP was measured immediately before and 45 min after clonidine administration. Bicuculline was given at the doses of 0.5, 1.0 and  $1.5\text{mg/kg}$  and picrotoxin at the doses of 0.5, 1.0, 1.5,  $2.0\text{mg/kg}$  intraperitoneally. SBP was recorded before and 15 min after GABA<sub>A</sub> antagonist administration. To study the combined effects of clonidine and GABAergic antagonists, bicuculline was injected at the doses of 0.5, 1.0 and  $1.5\text{mg/kg}$  and picrotoxin at the doses ranging from 0.5 to  $2.0\text{mg/kg}$ . In this experiment clonidine doses were  $20\mu\text{g/kg}$  in WKY and 20 or  $10\mu\text{g/kg}$  in SHR. The antagonists were given 30 min after clonidine.

### *Biochemical studies*

Since indirect measurement of blood pressure is stressful to the animals and may alter the amino acid content of the brain, additional group of rats were used for the study of changes in GABA chemistry after administration of drugs. Two groups of rats were injected i.p. with the GABA transaminase inhibitor aminooxyacetic acid at a dose of  $50\text{mg/kg}$  according to Yoneda et al. (1983). 15 min later one group received saline and second one clonidine. All rats were decapitated 60 min after AOAA injection for determination of GABA content. The difference in GABA content between AOAA alone and AOAA with clonidine treated groups was used to determine the GABA turnover. To prevent post mortem increase in GABA content, rats before decapitation were injected with the glutamic acid decarboxylase inhibitor 3-mercaptopropionic acid ( $100\text{mg/kg}$  i.p.), according to Carmona et al. (1980). GABA accumulation in the hypothalamus and the pons-medulla was determined. The tissues were isolated according to Balcom et al. (1975). Frozen tissues were homogenized in a Potter-Elvehjem homogenizer and centrifuged (20 min,  $8000g$ ,  $4^\circ\text{C}$ ). The clear supernatants were stored at  $-20^\circ\text{C}$  for up to 24 h. The GABA concentration was determined spectrofluorimetrically according to Lowe et al. (1958) with the modification of Uchida and O'Brien (1964). Fluorescence was determined with a Shimadzu spectrofluorometer at 380/450 nm. GABA content was expressed in nmol/mg protein. The detection limit of GABA was 0.1 nM. The protein

concentration was determined by the method of Lowry et al. (1951) using bovine serum albumin as standard.

### Chemicals

Clonidine hydrochloride (CLON) and bicuculline methobromide (BIC) were purchased from Sigma Chemical Co (USA) and picrotoxin (PIC) from Aldrich chemical Co (FRG). All drugs were dissolved in saline. Picrotoxin solution was adjusted to pH 7.4 with 0.5 N NaOH and the final volume made up of 0.9% NaCL. The solutions were injected intraperitoneally in a volume of 1 ml/kg. All other compounds were of the highest quality available commercially.

### Data analysis

All values are expressed as means  $\pm$  S.E.M. The statistical significance was calculated by using Student's t-test.


## Results

Basal SBP was significantly higher in SHR as compared to WKY rats (Table 1.) In both strains clonidine induced a dose-dependent decrease of systolic blood pressure. Nonetheless, the drug was more effective in SHR than in WKY rats. Thus, to achieve the similar decreases of blood pressure in WKY as in SHR it was necessary to double the dosage. There was no influence of picrotoxin or bicuculline on SBP at the doses ranging from 0.5 to 2.0 mg/kg in both strains (Table 1). The GABA<sub>A</sub> receptor antagonists counteracted dose dependently the hypotension of clonidine. The effectiveness of picrotoxin in reducing the clonidine action is much higher in SHR than in WKY rats. The antihypertensive effect of clonidine administered at a dose 20  $\mu$ g/kg was re-

**Table 1.** Systolic blood pressure response to clonidine and GABA<sub>A</sub> receptor antagonists administration. The data are presented as mean  $\pm$  SEM (n = 10)

| Treatment   |               | SBP (mmHg)   |               |
|-------------|---------------|--------------|---------------|
|             |               | WKY          | SHR           |
| Control     | 1 ml/kg       | 138 $\pm$ 3  | 196 $\pm$ 5   |
| Clonidine   | 5 $\mu$ g/kg  | 117 $\pm$ 4* | 160 $\pm$ 3** |
|             | 10 $\mu$ g/kg | 105 $\pm$ 5* | 149 $\pm$ 3** |
|             | 20 $\mu$ g/kg | 96 $\pm$ 9** | 131 $\pm$ 7** |
|             | 1 ml/kg       | 137 $\pm$ 6  | 188 $\pm$ 4   |
| Picrotoxin  | 0.5 mg/kg     | —            | 177 $\pm$ 6   |
|             | 1.0 mg/kg     | 126 $\pm$ 6  | 185 $\pm$ 5   |
|             | 1.5 mg/kg     | 141 $\pm$ 3  | 181 $\pm$ 7   |
|             | 2.0 mg/kg     | 142 $\pm$ 4  | 177 $\pm$ 6   |
| Control     | 1 ml/kg       | 135 $\pm$ 5  | 187 $\pm$ 7   |
| Bicuculline | 0.5 mg/kg     | 124 $\pm$ 6  | 182 $\pm$ 4   |
|             | 1.0 mg/kg     | 134 $\pm$ 4  | 185 $\pm$ 2   |
|             | 1.5 mg/kg     | 131 $\pm$ 3  | 186 $\pm$ 4   |

\* P < 0.01; \*\* P < 0.001 compared with vehicle group.




**Fig. 1.** Effect of picotoxin on hypotension induced by clonidine in conscious SHR and WKY rats. ■ CLON; □ CLON plus PIC. Number in parentheses indicates the dose of clonidine alone, others show doses of picotoxin combined with clonidine. SBP was measured 45 min after CLON administration. Each value is the mean  $\pm$  SEM of 7–9 rats. Statistical significance: \*  $P < 0.05$ , \*\*  $P < 0.001$ , \*\*\*  $P < 0.0001$  vs. controls

duced by picotoxin at a dose 1 mg/kg to 44% and 17% of its original value in SHR and WKY, respectively. This phenomenon occurred also when equivalent hypotensive doses of clonidine were used, that is 10  $\mu$ g/kg in SHR and 20  $\mu$ g/kg in WKY (Fig. 1). Similar effect was observed after administration of bicuculline in combination with clonidine. Clonidine hypotension was diminished by bicuculline in a dose related fashion. The hypertensive rats were more sensitive to antagonistic effects of bicuculline than normotensives (Fig. 2). It was found that clonidine elevated the GABA turnover in the studied areas in SHR and WKY rats (Fig. 3). Increase of GABA turnover was significantly higher in the hypothalamus than in the pons-medulla, in both strains. Although, the effect of clonidine was weaker in SHR than in WKY rats. Initial GABA content was also lower in hypothalamus and the pons-medulla in SHR in comparison with WKY i.e. 44 and 35 nmol GABA/mg protein and 78 and 71 nmol GABA/mg protein, respectively.


### Discussion

The present data demonstrate the differences between SHR and WKY rats either in the GABA<sub>A</sub> receptor antagonists action on clonidine hypotension or



**Fig. 2.** Effect of bicuculline on clonidine-induced hypotension in conscious SHR and WKY rats. ■ CLON; □ CLON plus BIC. \*  $P < 0.05$ , \*\* $P < 0.0001$ . Other details as in Fig. 1

in GABA turnover rate after drug injection. It should be kept in mind that the both GABA<sub>A</sub> antagonists counteract the clonidine hypotension more effectively in SHR. Since bicuculline and picrotoxin given alone did not affect systolic blood pressure, this antagonism cannot be explained by a direct pharmacodynamic interaction. The same observation was made in our previous studies with muscimol (Jastrzębski et al., 1993). It is well established that these GABAergic antagonists interfere with GABA<sub>A</sub> receptor complex i.e. as picrotoxin by blockade of the chloride ion channels or as bicuculline by competition with GABA for the recognition site (Soltis and DiMicco, 1991). It is possible that antihypertensive action of clonidine relies on the GABA<sub>A</sub> receptor stimulation. Thus, the reduction of the clonidine antihypertensive effectiveness by picrotoxin or bicuculline could be related to the antagonistic action of these agents at the level of the GABA<sub>A</sub> receptor complex. Presently, there is a wide body of evidence showing the impairment of central GABAergic system in the hypertension (Czyżewska-Szafran et al., 1989; Sasaki et al., 1990; Singewald et al., 1992). This may indicate that the stronger impact of GABA antagonists on clonidine hypotension in SHR can be due to the downregulation of GABAergic system. It should be noted, that our results are in contrast with those found by Marmo et al. (1987). We believe that a lack of differences between SHR and WKY rats in their studies may simple be dependent on the fact that the time of observation was not well selected.



**Fig. 3.** AOAA-induced GABA accumulation after clonidine 10 $\mu$ g/kg (SHR) and 20 $\mu$ g/kg (WKY) (AOAA alone = 100%) Effect of clonidine on hypothalamus and pons-medulla GABA accumulation induced by AOAA in rats. Clonidine was injected 15 min after AOAA, 50 mg/kg i.p. GABA accumulation was determined 60 min after injection of AOAA. The effects of clonidine on AOAA-induced GABA accumulation are shown in percent compared to the individual control group which was treated with AOAA alone together with clonidine treated group. For these calculations, the GABA content determined after AOAA alone in the respective control group was used as 100%. Data are means  $\pm$  SEM of 9–11 rats per time. Significant differences between GABA accumulation in groups treated with clonidine plus AOAA compared to the individual time-matched group treated with AOAA alone are marked by asterisk \* $P < 0.05$  \*\* $P < 0.001$ . Average GABA contents in rats treated with AOAA alone (mean  $\pm$  SEM of 9–11 rats) were as follows (all values in nmol/mg protein): hypothalamus 125  $\pm$  7 (WKY), 73  $\pm$  4 (SHR), pons-medulla 91  $\pm$  6 (WKY), 49  $\pm$  3 (SHR) AOAA-induced GABA accumulation after clonidine 10 $\mu$ g/kg (SHR) and 20 $\mu$ g/kg (WKY) (AOAA alone = 100%)

The present study argues the weaker effect of clonidine on GABA turnover in the hypothalamus and pons-medulla in SHR than in WKY rats. Some reports (Hambley et al., 1984; Wible et al., 1989) provide evidence that particularly in these areas abnormalities occur in GABAergic inhibition. In our previous experiments we also indicated that the basal rate of GABA turnover in the hypothalamus was significantly lower in hypertensive rats than in normotensive ones (Czyżewska-Szafran and Wutkiewicz, 1986). Similar results for the hypothalamus were reported by Sasaki et al. (1992). Therefore, it could be explained that the less potent clonidine effect in SHR is connected with the impairment of the GABAergic system in hypertension.

Our results indicate that the spontaneously hypertensive rats are more sensitive to the antihypertensive action of clonidine than the normotensive rats. It is consistent with the results reported previously by other authors (Dalas et al., 1986; Tibrica et al., 1988) by using similar doses and routes of

drug administration. From our data it can be seen that clonidine stimulates GABAergic system function. Thus, it is very likely that one of the possible mechanisms of the antihypertensive action of clonidine consists of restoration of the normal GABAergic neurotransmission. It is well known that in the essential hypertension the function of many neurotransmitter systems controlling arterial blood pressure is changed (Schultz et al., 1988; Lindhorst et al., 1993; Yang et al., 1994). As mentioned in the introduction hypotensive effect of clonidine is also induced by various neurotransmitter systems. Thus, with respect to the higher effectiveness of clonidine in hypertensive animals and simultaneously with the weaker drug effect on the GABA turnover we confirm that not only the GABAergic system is involved in the antihypertensive action of clonidine.

In summary, we postulate that the downregulation of the GABAergic system observed in hypertension may be compensated by the regulatory action of clonidine.

### References

- Balcom GJ, Lenox RH, Meyerhoff JL (1975) Regional gamma-aminobutyric acid levels in rats brain determined after microwave fixation. *J Neurochem* 24: 609–613
- Carmona, E, Gomes C, Trolin G (1980) On the importance of GABAergic neurons for the AOAA-induced accumulation of GABA in the rat brain. *Naunyn-Schmiedeberg Arch Pharmacol* 313: 221–224
- Czyżewska-Szafran H, Wutkiewicz M (1986) The activity of glutamate decarboxylase and the turnover of  $\gamma$ -aminobutyric acid in spontaneously hypertensive rats. *Pol J Pharmacol Pharm* 38: 135–141
- Czyżewska-Szafran H, Wutkiewicz M, Remiszewska M, Jastrzębski Z, Czarnecki A, Danysz A (1989) Down-regulation of the GABAergic system in selected brain areas of spontaneously hypertensive rats (SHR). *Pol J Pharmacol Pharm* 41: 619–627
- Czyżewska-Szafran H, Jastrzębski Z, Remiszewska M, Wutkiewicz M (1991) Effect of clonidine on blood pressure and GABAergic mechanism in spontaneously hypertensive rats. *Eur J Pharmacol* 198: 115–120
- Dalas S, Laverly WH, McNeil JR (1986) Clonidine fails to reduce pressor responsiveness of conscious spontaneously hypertensive rats to vasopressin. *Can J Physiol* 64: 284–289
- Hambley J, Johnston G, A, R, Shaw J (1984) Alteration in a hypothalamic GABA system in the spontaneously hypertensive rat. *Neurochem Int* 6: 813–821
- Jastrzębski Z, Coźlińska B, Czyżewska-Szafran H (1993) Pharmacodynamic interaction of clonidine and muscimol in hypertension. *Res Commun Chem Pathol Pharmacol* 81: 113–116
- Karege F, Gaillard JM (1990) Metabolism time-course of monoamines in rat brain after low dose of clonidine. *Biog Amine* 7: 37–48
- Lindhorst ACE, De Jong W, De Boer T, Versteeg DHG (1993) Dopamine D<sub>1</sub> and D<sub>2</sub> receptors in the caudate nucleus of spontaneously hypertensive rats and normotensive Wistar-Kyoto rats. *Brain Res* 602: 119–125
- Lowe JP, Robins E, Eyerman GS (1958) The fluorimetric measurement of glutamic decarboxylase and its distribution in brain. *J Neurochem* 3: 8–12
- Lowry OH, Rosebrough NY, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* 193: 265–275
- Marmo E, Filippelli W, Manazzo R, Russo S, Cazzola M, Vacca C, Ross F (1987) Participation of GABAergic mechanisms in the hypotensive and bradycardic effects

- of clonidine: experimental study in conscious normotensive and hypertensive rats. *Neuropharmacology* 26: 1525–1528
- Pittaluga A, Raiteri M (1988) Clonidine enhances the release of endogenous gamma-aminobutyric acid through  $\alpha_1$  and  $\alpha_2$  presynaptic adrenoceptors differentially located in rat cerebral cortex subregion. *J Pharmacol Exp Ther* 245: 682–686
- Sasaki S, Nakata T, Kawasaki S, Hayashi J, Oguro M, Takeda KK (1990) Chronic central GABAergic stimulation attenuates hypothalamic hyperactivity and development of spontaneous hypertension in rats. *J Cardiovasc Pharmacol* 15: 706–713
- Sasaki S, Kuwabara T, Yoshitomu T, Yoneda Y, Takenako K, Takesako T, Tanaka M (1992) Decreased hypothalamic and medullary GABA turnover in spontaneously hypertensive rats. *Cardiovasc Res* 26: 261–264
- Schultz BG, Schröder G, Stock G (1988) Contribution of serotonergic systems to maintenance of blood pressure in anaesthetized normotensive Wistar-Kyoto and conscious spontaneously hypertensive rats. *Drugs* 36 [Suppl] 1: 102–104
- Singewald N, Pfitscher A, Philippu A (1992) Effects of gamma-vinyl GABA (vigabatrin) on blood pressure and body weight of hypertensive and normotensive rats. *Naunyn-Schmiedeberg Arch Pharmacol* 345: 181–186
- Soltis RP, DiMicco JA (1991) Interaction of hypothalamic GABA<sub>A</sub> and excitatory amino-acid receptors controlling heart rate in rats. *Am J Physiol* 261: R427–R433
- Tibirica E, Feldman J, Bousquet P (1988) Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anesthetized rats. *J Pharmacol Exp Ther* 244: 1062–1066
- Uchida T, O'Brien D (1964) The effect of hydrazines on rat brain 5-hydroxytryptamine, norepinephrine and gamma-aminobutyric acid. *Biochem Pharmacol* 13: 725–730
- Weekley LB, Phan T, Narasimhachari N, Johanssen J, Boadle-Biber MC (1985) Effect of clonidine on the activity of tryptophan hydroxylase from rat brain stem following in vivo or in vitro treatment. *Biochem Pharmacol* 34: 1549–1557
- Wible JH Jr, Luft FC, Di Micco IA (1988) Hypothalamic GABA suppresses sympathetic outflow to the cardiovascular system. *Am J Physiol* 254: R680–R687
- Wible JH Jr, Di Micco IA, Luft FC (1989) Hypothalamic GABA and sympathetic regulation in spontaneously hypertensive rats. *Hypertension* 14: 623–628
- Yang CH, Chan JYH, Pan JT, Chan SHH (1994) Differential neuronal responses to angiotensin III from the subfornical organ of normotensive and spontaneously hypertensive rats. *Brain Res* 638: 169–174
- Yoneda Y, Kanmori K, Ida S, Kuriyama K (1983) Stress-induced alterations in metabolism of  $\gamma$ -aminobutyric acid in rat brain. *J Neurochem* 40: 350–355

**Authors' address:** Prof. Halina Czyżewska-Szafran, Department of Pharmacology, Drug Institute, 30/34 Chelmska Str., 00-725 Warsaw, Poland, Fax (48) 41-06-52

Received October 31, 1997